The Spectrum of Cutaneous Adverse Events During Encorafenib and Binimetinib Treatment in B-Rapidly Accelerated Fibrosarcoma-Mutated Advanced Melanoma

    Natalie P Graf, Peter Koelblinger, N. Galliker … Simone M. Goldinger
    Studysummary In this study, encorafenib combined with binimetinib was well tolerated in melanoma patients, resulting in relatively few cutaneous adverse events compared to other BRAF and MEK inhibitors.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on onlinelibrary.wiley.com →
    Discuss this study in the Community →

    Research cited in this study 2

    1. RASopathic Skin Eruptions During Vemurafenib Therapy PLoS ONE · 2013
    2. Cutaneous Manifestations of Dabrafenib: A Selective Inhibitor of Mutant BRAF in Patients with Metastatic Melanoma British Journal of Dermatology · 2012